A research team at the Thayer School of Engineering at Dartmouth received a $2.5 million grant to develop and test a device meant to help surgeons detect and remove prostate cancer cells that would otherwise be missed during surgery. The five-year grant, awarded by the National Cancer Institute, part of the National Institutes of Health, will focus…
Genetic material collected in routine cervical cancer screenings could be used to screen for ovarian cancer several years before disease symptoms are evident, possible speeding diagnosis and treatment, a study suggests. The study, “Detection of TP53 Clonal Variants in Papanicolaou Test Samples Collected up to 6 Years Prior to High-Grade Serous Epithelial Ovarian Cancer Diagnosis,” was…
Odonate Therapeutics announced that tesetaxel, together with a reduced dose of capecitabine, improved progression-free survival in metastatic breast cancer patients taking part in a Phase 3 clinical trial. Median progression-free survival (PFS) — the time lived until disease progression or death due to any cause — improved by 2.9 months on the combined therapy regimen as compared…
Throughout September for Blood Cancer Awareness Month, the Leukemia & Lymphoma Society (LLS) is asking the public to join its commitment to research, education, advocacy, and patient support. Blood cancers, including multiple myeloma, are diagnosed every three minutes in the U.S. Those who live with these conditions must also deal with challenges caused by COVID-19. “The global…
Tessa Therapeutics’ investigational CD30 CAR-T cell therapy is safe and leads to a high rate of strong and sustained responses in people with relapsed or treatment-resistant Hodgkin’s lymphoma, according to data from two Phase 1/2 trials. The trial findings were reported in “Anti-CD30 CAR-T Cell Therapy in Relapsed and Refractory Hodgkin Lymphoma,” a study published…
The first three patients have been dosed in a Phase 2a clinical trial investigating Annovis Bio‘s lead compound ANVS401 as a treatment for people with early Alzheimer’s and Parkinson’s diseases, the company said. The trial (NCT04524351) will recruit up to 68 participants at 15 sites scattered across the U.S. Thus far, only the sites in Florida…
The Institute for Prostate Cancer Research (IPCR), a collaborative effort between the Fred Hutchinson Cancer Research Center and UW Medicine, has launched a video series of exercises especially designed to help men with prostate cancer maintain a healthy routine of physical activity. According to Lauren Brady, PhD, the postdoctoral research fellow at Fred Hutch who led…
The National Ovarian Cancer Coalition (NOCC) is hosting its annual Together in Teal — No Boundaries fundraiser as a nationwide virtual celebration on Sept. 26, it announced in a press release. Presented during National Ovarian Cancer Awareness Month, the event raises money to support early disease awareness, quality of life for survivors, scientific research, and community…
The U.S. Food and Drug Administration (FDA) has granted priority review to Oncopeptide’s application seeking accelerated approval of melflufen (melphalan flufenamide) plus dexamethasone for people with relapsed or refractory multiple myeloma (RRMM). The new drug application was submitted in July and based on promising data from the HORIZON Phase 2 trial (NCT02963493). It is specific for people with triple-refractory disease —…
The U.S. Food and Drug Administration (FDA) has issued a complete response letter stating that it will not approve the combination of Keytruda (pembrolizumab) plus Lenvima (lenvatinib) as a first-line treatment for people with advanced unresectable hepatocellular carcinoma (HCC). According to a press release, the decision was made on the basis that there isn’t evidence this treatment combination…
